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from PQRI and HEDIS 2010 requirements; pharmacy measures included 14 PQA 
measures being tested for these diseases. Measures were reviewed to identify: 1) type 
(process/outcome) 2) constructs; and 3) data requirements (pharmacy, medical, labora-
tory). RESULTS: Forty-eight measures were included (13 HEDIS, 21 PQRI, 14 PQA). 
HEDIS and PQRI measures for diabetes and dyslipidemia emphasize outcomes 
(achievement of Hgb A1c and LDL goals) and % receiving recommended screenings, 
while PQA measures emphasize process (adherence as gaps in therapy and proportion 
of days covered), excessive doses of diabetes medications, and suboptimal treatment 
(% on diabetes prescription without an ACEI or ARB). HEDIS, PQRI, and PQA 
measures for asthma assess use of controller medications, though 1 PQA measure also 
assesses overuse of beta agonists. Differences in the types and constructs of measures 
suggest opportunities for alignment. A bi-level framework that employs reporting 
pharmacy measures among patients who have not met the physician measure may 
facilitate a team approach for diabetes and hypertension quality, though this 
would only be feasible for organizations holding both medical and pharmacy data. 
CONCLUSIONS: Medication quality measures are of increasing importance, yet 
available physician and pharmacy measures differ. Findings suggest that testing a 
bi-level framework for diabetes and hypertension pharmacy quality measurement 
would be worthwhile.
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THE ROLE OF AUTHORIZED GENERICS IN THE PRESCRIPTION DRUG 
MARKETPLACE
Shcherbakova N, Shepherd M, Lawson K, Richards K
University of Texas at Austin, Austin, TX, USA
OBJECTIVES: Authorized generics (AGs) are products manufactured by a patent 
holder but marketed by a subsidiary or a third party company. AGs might increase 
competition and reduce generic prices when launched during the 180-day exclusivity 
period of an independent generic(s) (IGs). AGs launched during IG exclusivity might 
also present a long-term disadvantage to consumers by delaying timely entry of gener-
ics. The objectives of this study were: 1) to determine the trend in market share of 
AGs during the ﬁrst six months for drugs launched with a ﬁrst-ﬁler(s) 180-day exclu-
sivity; 2) to determine the trend in market share of AGs for the ﬁrst six months for 
drugs launched without ﬁrst-ﬁler(s) exclusivity. METHODS: Five drugs were selected 
as cases to assess the effect of AGs launched during the exclusivity of IGs on market 
share of the brand and generic products. Each product selected had three subcatego-
ries: a brand name drug, an AG and at least one IG on the market. The unit of analysis 
was the number of prescriptions dispensed, without regard to the dispensed quantity. 
RESULTS: At the end of the ﬁrst year, market shares of AGs launched with the 
exclusivity of an IG in the cases of Zocor®, Proscar® and Norvasc® were 37%, 52% 
and 49%, respectively. Meanwhile, market shares of AGs launched without the 
exclusivity of an IG in the cases of Arava® and Ambien® were 21% and 14%, 
respectively. CONCLUSIONS: AGs launched during IG exclusivity dominated the 
market and had the largest market share when compared to any other single market 
participant for the case. AGs launched during IG exclusivity obtain a dominant market 
share position and in the long run might discourage IG companies from timely generic 
introductions. Policy limiting the entry of AGs during the exclusivity of IG exclusivity 
might prevent delayed generic entry.
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DESCRIPTION AND EVALUATION OF THE KNOWLEDGE OF THE 
BRASILIA POPULATION FOR THE POLITICS OF ECONOMIC MEDICINE 
REGULATION IN BRAZIL
Araujo MAM, Rebelo FM, Freitas PC, Alaver RT
ANVISA, Brasilia, DF, Brazil
OBJECTIVES: The primary objective was to evaluate the knowledge of the drugstore 
consumers from Brasilia and workers of ANVISA, for the regulation of prices of 
medicines. The speciﬁc objectives were to assess the knowledge of the populations on 
PMC, different price of generic medicines, estimate monthly expenses of the two 
samples and a preliminary comparative analysis between the two samples. METHODS: 
The study developed is a cross descriptive and analytical study. Based in the applica-
tion of different questionnaires for to assess the knowledge about regulation of prices 
of medicines and consumption habits of consumers interviewed in the door of the 
drugstore and workers of ANVISA. The research was conducted by sampling accord-
ing to the location of the drugstore and in accordance with the area of capacity in the 
workers of ANVISA. RESULTS: there were interviewed 105 consumers in drugstores 
and 140 workers of ANVISA. When asked about the existence of market regulation 
of drugs, 51.43% and 87.14% of drug users and employees of ANVISA, respectively, 
said there is regulation of these products. About the PMC, the knowledge was 20.00% 
of respondents in pharmacies and 57.86% of the employees of ANVISA. Despite of 
the relative knowledge of PMC, only 01 of the respondents knew where consumers 
search the PMC, and the employees of ANVISA, 29 knew the sources of research. 
Although the poor knowledge on the regulation of prices, 84.76% of consumers 
interviewed considered this activity exerted by the government as important. CON-
CLUSIONS: Although the population consider important that the prices of medicines 
are regulated by the government, the knowledge of the regulation is small, even on 
the tools of consumer protection.
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INDEPENDENT RETAIL PHARMACY ATTRIBUTES, INSURER 
REIMBURSEMENT, AND THE IMPLICATION ON THE PROPOSED 
COLLECTIVE BARGAINING LAW
Xie Y, Urmie JM, Brooks JM, Doucette WR
University of Iowa, Iowa City, IA, USA
OBJECTIVES: 1) To examine whether small individual provider attributes affects 
reimbursement between insurer and independent retail pharmacies, and 2) to under-
stand the implication of our results on the potential impact of the proposed community 
pharmacy collective bargaining law. METHODS: Data were collected and compiled 
from four sources: a national mail survey to independent pharmacies, National 
Council for Prescription Drug Programs Pharmacy database, 2000 U.S. Census and 
2006 Economic Census data. Pharmacy bargaining power was calculated using the 
costs, cash prices and reimbursement rates of a brand name drug Lipitol and a generic 
drug Lisinopril acquired from the survey. Key independent variables include individual 
pharmacy attributes and local market structure measures. RESULTS: Reimbursements 
varied substantially across pharmacies. For Lipitor, best reputation (β = 0.101), easiest 
accessibility (β = 0.067), pharmacy ownership concentration index (β = 0.104) and 
area per capita income (β = −0.165) are signiﬁcant predictors of pharmacy bargaining 
power. For Lisinopril, only easiest access (β = 0.082) and per capita income (β = 
−0.068) are found to be signiﬁcant. CONCLUSIONS: Pharmacies with the best repu-
tation, easiest access and facing less competition in its market receive higher reimburse-
ment rates for brand name drugs. An independent pharmacy with the best reputation 
and easiest access and with average dispensing volume would receive $167,688 more 
in reimbursement a year than a pharmacy that doesn’t have the best reputation and 
easiest access. Our results suggest that the current third party contracting practice 
rewards pharmacies with favorable attributes with higher reimbursements. Our results 
also imply that a collective bargaining law for independent pharmacies is likely to 
beneﬁt those pharmacies currently receiving below average reimbursement rates due 
to weaker market positions, and would have the potential effect of raising costs and 
removing incentives for pharmacies to maintain the attributes that are valuable to 
customers.
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DIFFERENCES IN CLINICIAN REPORTED EASE OF USE BETWEEN 2 
HEMOSTASIS TREATMENT METHODS: RESULTS FROM A RANDOMIZED 
CONTROLLED STUDY
Rupnow MF1, McCormack J2, Vernon M2, Batiller J3, Hammond J4
1Ethicon, Inc., Somerville, NJ, USA, 2United BioSource Corporation, Bethesda, MD, USA, 
3Ethicon, Inc, Somerville, NJ, USA, 4Ethicon, Inc, Somverville, NJ, USA
OBJECTIVES: To evaluate treatment group differences in clinician reported ease of 
use between Fibrin Pad (FP) and Surgicel for hemostasis in subjects with mild or 
moderate bleeding using a novel survey tool. METHODS: The Ease of Use Question-
naire (EUQ) was used as part of a randomized, controlled, clinical study of FP versus 
Surgicel for intra-operative hemostasis. Subjects were randomized at 11 institutions 
with a 2:1 FP to Surgicel ratio. Additional subjects were enrolled in the non-random-
ized phase and treated with FP. Subjects were stratiﬁed according to bleeding severity. 
Up to the ﬁrst three subjects completed the EUQ at each institution. The ﬁnal sample 
was N = 20 FP and N = 8 Surgicel (randomized) and N = 2 FP (non-randomized). 
The EUQ is a 19-item instrument evaluating clinicians’ perceptions and preferences 
for hemostasis products on ﬁve subscales (Ease of Use, Satisfaction with Product 
Properties and Efﬁciency, Conﬁdence in Efﬁcacy, Global Conﬁdence, and Global 
Satisfaction).1 Differences in ease of use between treatment groups were evaluated 
using ﬁve ANCOVA models where subscale scores were the dependent variables, 
treatment group was the independent variable, and severity of bleeding was controlled 
for as the covariate. RESULTS: Mean subscale scores for Conﬁdence in Efﬁcacy (FP 
= 4.70 vs. S = 3.50), Global Conﬁdence (FP = 4.70 vs. S = 4.13) and Global Satisfac-
tion (FP = 4.85 vs. S = 4.04) were signiﬁcantly higher for the FP group as compared 
to the Surgicel group (all p < 0.05). Mean subscales scores for Ease of Use (FP = 4.82 
vs. S = 4.66) and Satisfaction (FP = 4.71 vs. S = 4.34) were higher for the FP group, 
but non-signiﬁcant. CONCLUSIONS: Physicians reported higher ease of use, satisfac-
tion, and global conﬁdence with FP for hemostasis in mild to moderate bleeding. 
Non-signiﬁcant results in the Ease of Use and Satisfaction subscales likely resulted 
from small sample sizes. Future studies should evaluate ease of use in the full range 
of bleeding severities and larger sample sizes.
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ADVANCING THE EVIDENCE BASE FOR ORTHOTICS AND 
PROSTHETICS
Mohandas A, Thompson E, Goldfarb N
Jefferson School of Population Health, Philadelphia, PA, USA
OBJECTIVES: Limited information is currently available regarding outcomes related 
to orthotics and prosthetics (O&P). Rapidly emerging technologies in the O&P ﬁeld 
have increased the need for comparative effectiveness studies examining clinical, 
humanistic, and economic outcomes. The objective of this project was to establish and 
pilot test a patient registry for outcomes assessment. METHODS: A web-based survey 
system combining input from both O&P providers and their patients was developed 
and pilot-tested among nine O&P clinics across the country. The providers entered 
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data on patient demographics, functional status, and mobility, for consenting patients, 
and then the patients entered information regarding functional abilities, satisfaction, 
pain, quality of life and cost of care. RESULTS: A total of 43 patients participated in 
the pilot survey. Respondents were predominantly insured through Medicare (43%) 
and 68% were men. With regard to functional abilities, 19% of the consumers 
required help with at least one activity of daily living. The percent of consumers 
experiencing an improvement in their ability to perform activities such as exercise, 
walking, bathing and dressing independently, all after receiving their device ranged 
from 18% to 51 %. Consumers also reported improved mood (64.9%), high satisfac-
tion with their device (81.1%) and their provider (100%), and improved conﬁdence 
(73%) after using their device. Several patients reported problems with ability to pay 
the out-of-pocket costs for their device (12.5%) or to afford device repair costs (9%). 
CONCLUSIONS: Preliminary results suggest that collecting outcomes data on this 
population is feasible, and that patients are beneﬁting from their O&P devices, 
through improved functional ability and emotional status. The systematic collection 
of patient reported outcomes may help to demonstrate the comparative effectiveness 
and value of O&P devices, and ultimately inform health insurance coverage 
decisions.
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WHEN ARE DIAGNOSTIC LABORATORY TESTS COST-EFFECTIVE?  
A SYSTEMATIC REVIEW OF COST-UTILITY ANALYSES
Fang CH1, Otero HJ1, Greenberg D2, Neumann PJ1
1Tufts Medical Center, Boston, MA, USA, 2Ben-Gurion University of the Negev, Beer-Sheva, 
Israel
OBJECTIVES: Diagnostic laboratory tests may add critical information to guide 
treatment and improve patient outcomes, but payers have often questioned its value. 
We reviewed the methodology and results of published cost-utility analyses (CUAs) 
of laboratory tests through 2008. METHODS: We screened all papers related to labo-
ratory diagnostic tests in the Tufts Medical Center Cost-effectiveness Analysis Registry 
(www.cearegistry.org) which contains detailed information on over 2,000 published 
CUAs from 1976 to 2008. In addition to the standard auditing process, we recorded 
information on the reported test accuracy and IVD cost. We also captured whether 
any account was taken for potential value (or harm) unrelated to treatment conse-
quences such as the “reassurance value of testing” or additional anxiety produced by 
test information. RESULTS: We identiﬁed 141 published CUAs pertaining to diag-
nostic laboratory tests, which contained 433 separate incremental cost-effectiveness 
ratios (ICER). The number of publications has increased rapidly in recent years. The 
most common areas of clinical application were hematology/oncology (n = 42, 
29.8%), and OB/GYN (n = 36, 25.5%). Approximately 63% (89/141) of studies 
addressed the accuracy of the test. Only 10% (14/141) mentioned test safety or associ-
ated risks. A small number (n = 13, 9.2%) of CUAs mentioned or considered the 
potential value or harm of testing unrelated to treatment consequences. Over 55% of 
the reported ICERs were either dominant (more QALYs for less cost), or below 
$50,000 per QALY gained (in $US 2008). CONCLUSIONS: The number of CUAs 
evaluating laboratory tests technologies has increased substantially with applications 
to diverse clinical areas. The vast majority of CUAs have not attempted to measure 
the potential value or harms of diagnostic testing unrelated to treatment.
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THE BUDGET IMPACT OF ORAL NUTRITIONAL SUPPLEMENTS IN THE 
COMMUNITY SETTING IN THE NETHERLANDS
Nuijten M1, Freyer K2
1Ars Accessus Medica/Erasmus University Rotterdam, Jisp, The Netherlands, 2Nutricia 
Advanced Medical Nutrition, on behalf of the Dutch Industry Organisation of Children and 
Dietary Nutrition (VNFKD), Zoetermeer, The Netherlands
OBJECTIVES: To assess the budget impact of introducing oral nutritional supple-
ments (ONS), being a medical nutrition product, in elderly patients from the perspec-
tive of the society in The Netherlands in 2009. METHODS: A model was developed 
to calculate the budgetary impact of using ONS in patients who are eligible for ONS 
due to disease-related malnutrition (DRM). The analysis is based on the cohort of 
elderly patients (>65 years) in the community setting in The Netherlands in 2009. The 
budget impact of ONS was assessed using a linear decision analytic model reﬂecting 
cost functions related with DRM. The model allowed the assessment of the cost 
reductions resulting from improvement in DRM due to treatment with ONS. Clinical 
probabilities and resource utilization were based on clinical trials and published litera-
ture; cost data were from ofﬁcial price tariffs. RESULTS: The use of ONS leads to 
annual cost savings of 313.3 million (18.9%), when all eligible patients are treated. 
The additional costs of ONS (357.0 million) are more than balanced by a reduction 
on other health care costs (370.3 million). Sensitivity analyses were performed on all 
parameters, including duration of treatment with ONS and the proportion of DRM. 
These results showed that the use of ONS in all sensitivity analyses leads to cost 
savings. CONCLUSIONS: This budget impact analysis shows that the use of ONS in 
eligible elderly patients in the community setting leads to a positive impact on the 
national health care budget in The Netherlands.
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THE UTILIZATION OF PARENTERAL NUTRITION IN THE UNITED 
STATES
Liu FX1, Mercaldi K2, Turpin R1
1Baxter Healthcare Corporation, Deerﬁeld, IL, USA, 2United BioSource Corporation, 
Bethesda, MD, USA
OBJECTIVES: Parenteral nutrition (PN) is used with patients when oral or enteral 
nutrition isn’t possible or adequate. Compared to other therapeutic interventions, 
relatively little is known about the real-world use of PN, the characteristics of 
patients who receive it, or the incidence of adverse events. Our objective was to 
explore PN as it is currently utilized in the United States, using a large, nationally 
representative inpatient database. METHODS: We examined the Premier Perspec-
tiveTM database for all inpatients who received any PN between 2005 and 2007. 
Inpatients admitted with any outcome of interest (i.e., bacterial infection, hepatic 
dysfunction, hypoglycemia, acute cholecystitis, and phlebitis) were excluded. Hospital 
(e.g., bed size, geographic location, urban/rural status), patient (e.g., age, sex, comor-
bidities, severity), and PN characteristics were analyzed. RESULTS: Of over 11 
million inpatients in the database, 68,984 adult, 3,083 pediatric and 34,307 neonates 
received PN. The average age of the adult patients was 66. Whites had a dispro-
portionally higher probability of receiving PN (73.1%) than any other ethnic group. 
46.2% of PN adult patients received PN in hospitals with bed size of 250–499, 
followed by hospitals with bed size of 500–749 (31.5%), and hospitals with bed 
size 50–249 (20.3%). Among adult PN patients, 38.9% were diagnosed with a 
malignancy, followed by undernutrition 33.2%, renal failure 31.3%, diabetes 24.4%. 
peritonitis 9.0%, acute pancreatitis 8.4%, and cirrhosis 7.6%. Compared to neonates, 
the infection rates and bloodstream infection rates (BSI) of the adult population 
were much higher (infection, 49.0% vs. 10.7%; BSI 26.9% vs. 1.7%). Most patients 
were primarily diagnosed with intestinal or peritoneal adhesion with obstruction 
(ICD-9 560.81). The majority of PN adult patients used procedure of venous cath-
eterization (ICD-9 38.93). CONCLUSIONS: Large retrospective databases provide 
us with extraordinary insights to understand the characteristics of this vulnerable 
population and the real-world use of PN.
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OBJECTIVES: To assess the health economic impact of oral nutritional supplements 
(ONS), being a medical nutrition product, in elderly patients from the perspective of 
the society in The Netherlands in 2009. METHODS: This health economic analysis 
is based on a comparison of the use of ONS versus “no ONS” in patients who are 
eligible for ONS due to disease-related malnutrition (DRM). The base case analysis 
is based on a comparison in elderly patients (>65 years) in the community setting. The 
costs of the two treatment strategies ONS versus “no ONS” were assessed using a 
linear decision analytic model reﬂecting costs related with DRM. The model structure 
allowed for differences in costs for ONS and other resource utilization. Clinical prob-
abilities and resource utilization were based on clinical trials and published literature; 
cost data were from ofﬁcial price tariffs. RESULTS: The use of ONS reduces the total 
costs from 31353 to 31180, which corresponds with a 3173 (12.8%) cost savings per 
patient. The additional costs of ONS are more than balanced by a reduction on 
hospitalization costs. Sensitivity analyses were performed on all parameters, including 
the risk of hospitalization and improvement of DRM. These results showed that the 
use of ONS in all sensitivity analyses leads to cost savings. CONCLUSIONS: This 
health economic analysis shows that the use of ONS in elderly patients in the com-
munity setting is a cost-effective treatment in The Netherlands and is dominant over 
standard care without ONS: it leads to cost savings and a higher effectiveness.
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THE HEALTH ECONOMIC IMPACT OF ORAL NUTRITIONAL 
SUPPLEMENTS IN THE HOSPITAL SETTING IN GERMANY
Nuijten M1, Freyer K2
1Ars Accessus Medica/Erasmus University Rotterdam, Jisp, The Netherlands, 2Nutricia 
Advanced Medical Nutrition, Zoetermeer, The Netherlands
OBJECTIVES: To assess the health economic impact of oral nutritional supplements 
(ONS), being a medical nutrition product, in hospitalized patients from the society 
perspective in Germany in 2009. METHODS: This health economic analysis is based 
on a comparison of the use of ONS versus “no ONS” in hospitalized patients who 
are eligible for ONS due to disease-related malnutrition (DRM). The costs of the two 
treatment strategies ONS versus “no ONS” were assessed using a linear decision 
analytic model reﬂecting costs related with DRM. The model structure allowed for 
differences in costs for ONS and length of stay. Clinical probabilities and resource 
utilization were based on clinical trials and published literature; cost data were from 
ofﬁcial price tariffs. RESULTS: The use of ONS reduces the total costs from 34105 
to 33967, which corresponds with a 3138 cost savings per patient. The additional 
costs of ONS are more than balanced by a reduction on hospitalization costs. Sensitiv-
ity analyses were performed on all parameters, including length of stay and improve-
ment of DRM. These results showed that the use of ONS in all sensitivity analyses 
leads to cost savings. CONCLUSIONS: This health economic analysis shows that the 
use of ONS in patients in the hospital setting is a cost-effective treatment in Germany 
